Movano Inc. Provides Business Update and Reports Fourth Quarter 2021 Financial Results

About this update from Corvex, Inc.

[{"type":"text","content":"Conference call begins at 2:00 p.m. Pacific time today\n PLEASANTON, Calif., March 24, 2022 /PRNewswire/ -- Today, Movano Inc. (NASDAQ:MOVE) reported financial results for the three months ending December 31, 2021 and provided a business update. With a mission to empower and inspire you to live a healthier, happier life, the Company continues to develop its platform that will deliver purpose-driven healthcare solutions at the intersection of medtech and consumer devices.\n\n \n \n \n \n \n \n\n \nHighlights from the fourth quarter and recent weeks include the following:\nIn December 2021, Movano unveiled plans for its first product, the Movano Ring, as a part of its virtual participation at CES 2022. The smart ring and accompanying mobile app solution combines vital health metrics with personalized intelligent feedback and is designed to help women of all ages make lifestyle changes and take a more proactive approach to managing their health. The Movano Ring will measure heart rate, heart rate variability (HRV), sleep, respiration rate, temperature, blood oxygen saturation (SpO2), steps, calories and incorporate women-centric features and design. The Movano Ring is the Company's foundational product as it works toward FDA clearances to add medical data, including cuffless blood pressure and non-invasive glucose measurements. In the fourth quarter 2021, the Company completed its third and largest Institutional Review Board (IRB)-approved blood pressure clinical study with 110 participants at the Movano Clinical Lab. During the study, participants wore Movano's adjustable full finger ring prototype and the Company's wrist-worn wearable prototype along with a hospital-grade FDA-cleared vital signs monitor as the control. Movano is actively evaluating the results of the study. The Company is using three different calibration methods to analyze the accuracy of the blood pressure data and is making good progress. During the study, the Company also collected SpO2 and heart rate data. Based upon the analysis thus far, the Company believes the accuracy of the SpO2 and heart rate data will be commensurate with predicate devices that have received FDA clearance. Additionally, in February 2022, Movano completed its second IRB-approved glucose pilot study, which was conducted on 10 participants with diabetes in conjunction with an independen...

More updates from Corvex, Inc.